RxTrials Institute Drug Pipeline AlertEach Wednesday morning turn to the RxTrials Drug Pipeline Alert for the latest intelligence on the research and development of new drugs in high-cost therapeutic areas such as oncology/hematology, cardiovascular, pediatrics, respiratory and others. Weekly issues cover U.S. and international clinical trials, medical research, drug applications and co-development activities. Sign up today and receive your first issue of the Alert next Wednesday.Argos Begins Phase II Trial for Renal Cell Carcinoma Drug- September 16, 2008 Argos Therapeutics is launching a Phase IIa trial of its AGS-003 therapy in combination with sunitinib for the treatment of newly diagnosed advanced renal cell carcinoma (RCC).http://www.fdanews.com/newsletter/article?articleId=110414&issueId=11959 Final Patient Completes Phase III Trial for Fibromyalgia Treatment- September 16, 2008 The first Phase III pivotal clinical trial from Jazz Pharmaceuticals in studying JZP-6 for the treatment of fibromyalgia has been completed.http://www.fdanews.com/newsletter/article?articleId=110412&issueId=11959 Transdermal Patch for Osteoporosis Gets Promising Results- September 16, 2008 Zosano Pharma reported positive data from its Phase II study of its PTH patch, a transdermal patch formulation of parathyroid hormone (PTH), for the treatment of established osteoporosis.http://www.fdanews.com/newsletter/article?articleId=110415&issueId=11959 Botox Reduces Headaches in Phase III Trial, Allergan Says- September 16, 2008 Allergan has completed an analysis of its two Phase III clinical trials exploring the use of Botox for the treatment of chronic migraine.http://www.fdanews.com/newsletter/article?articleId=110411&issueId=11959 Medarex, BMS See Positive Results in Three Phase II Studies- September 16, 2008 Medarex and Bristol-Myers Squibb received promising survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV) who previously had been treated.http://www.fdanews.com/newsletter/article?articleId=110413&issueId=11959 Pfizer Pulls Dalbavancin Applications to Conduct More Trials- September 16, 2008 Pfizer is withdrawing all marketing applications for its dalbavancin drug to treat infections in adults, including methicillin-resistant Staphylococcus aureus (MRSA), following discussions with regulatory authorities.http://www.fdanews.com/newsletter/article?articleId=110410&issueId=11959 NPS Reports Positive Data for Treatment of Rare Bone Condition- September 16, 2008 NPS Pharmaceuticals received favorable interim data from its investigator-initiated Phase II trial of NPSP558, a proprietary recombinant full-length human parathyroid hormone for the treatment of hypoparathyroidism.http://www.fdanews.com/newsletter/article?articleId=110416&issueId=11959 Genta Gets Green Light to Continue Cancer Trial- September 16, 2008 An independent data monitoring board (DMB) has recommended that Genta continue enrolling patients in its Phase III trial using Genasense injections to treat advanced melanoma.http://www.fdanews.com/newsletter/article?articleId=110409&issueId=11959 Novartis Cancer Drug to Get Priority Review- September 16, 2008 The FDA has granted priority review to Novartis’ kidney cancer treatment RAD001, an investigational drug studied in a Phase III trial for multiple tumor types.http://www.fdanews.com/newsletter/article?articleId=110408&issueId=11959 FDA Approves Rexahn Phase II Trial- September 16, 2008 Rexahn Pharmaceuticals received FDA approval to begin its Phase II trials with Serdaxin for the treatment of major depressive disorders.http://www.fdanews.com/newsletter/article?articleId=110417&issueId=11959 |